Alparu Urbano and Jose Maria Morada.
Patients with Human immunotherapy virus From Spain Congrats!After the Minister of Health recently, Monica Garcia, They updated the pharmaceutical protocols and financing standards to allow access to Car treatments with people with this infection Which provides uncovered viral load. This news is abandoned by the Spanish network of advanced treatments (sharp) As “success, since the final goal of New techniques and medicines It is that the largest possible number of patients benefit, from now on, will pass in the national health system (SNS) “.
One of the main Tyraf characters, Jose Maria Morala, crosses in Medical writing His conviction that this measure is an essential step in eliminating discriminatory obstacles and improving fairness in National health system (SNS): “The legislative frame will be placed so that this type of patient is You don’t have additional barriers They have access to Medicines that are high cost. now, Central mandate The balance of cases and benefits is measured by the case. “
Another evaluation is made indicating the same line that Morleda described by álvaro urbanoCAR-T Program Coordinator Clínic-Instituto de Research Biomédicas August Pi i Sunyer (Idibaps): “This is a great initiative, because these patients have a very similar response or equal response Population who does not have HIV. So far, he described the medical capabilities, since these patients have not been included in clinical trials, they were hesitant to give them. “
|
URBAN: “CAR-T is short and medium-term toxicity is very similar to the toxicity of patients who do not have HIV.”
|
Urban areas confirm that when Bibliography of HIV“One realizes the possibility of entering a complete remission of Car-T that occurred in a series of patients. In addition, short and medium toxicity is also also It is very similar to patients who do not have HIV“.
Long -term immunity, the next step
What is essential at this time, according to the expert, “is an analysis of the effect on the patient of these characteristics, such as Long -term immunity If the treatment affects them more or less. The ministry’s proposal, which will be implemented by the Spanish Agency for Medicines and Health Products (AEMPSIt is a success according to URBAN, although he realizes that “the answer remains many questions, in addition to the fact that it is necessary to preserve a Access to treatment throughout SNS“.
To date, when a clinical trial has been performed using Car-T, a blood specialist confirms that “what kind of immune deficiency will cause Car-T 19But if a study of the population with HIV has not followed it, it may be completely discriminatory. It has already been observed that if they are controlled, the results are the same, so SNS is looking to reduce this distinction in the root. “
Related medical needs
With this establishment of patients with HIV in SNS, Moraleda confirms that Spain “will include a strong set of Especially complex patients And they also have a need for a medical treatment related to TAdvanced Erapia like Car-T“In addition, the option is convinced that it is an extension of the entitlement,” which is the justice of this group. “
|
Morleda: “The new protocols will expand the benefit of the group is justice”
|
To date, people with HIV have been excluded Access protocols For these treatments due to the lack of clinical data It will support their safety and effectiveness In this group, a direct result of the systematic exclusion of these people in clinical trials.
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
